AZN vs EMBC: fair value comparison
AstraZeneca PLC and Embecta Corp. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. AZN carries the stronger quality grade.
| AZN | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $156.93 | $3.72 |
| 12-month range | $156.06–$202.39 | $3.29–$14.27 |
| Sector rank | #6 of 113 Healthcare | #3 of 113 Healthcare |
| Quality grade | B | C- |
| Momentum grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AZN fair value analysis · EMBC fair value analysis